Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation - Pathology
Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds | Science Advances
Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment | npj Precision Oncology
Immunotherapy and targeted therapy combinations in metastatic breast cancer - The Lancet Oncology
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors - Rezasoltani - 2021 - Cancer Medicine - Wiley Online Library
Enhancing anti-tumour efficacy with immunotherapy combinations - The Lancet
Biomarkers in Cancer Immunotherapy - Cancer Research Institute
Systemic Immunity Is Required for Effective Cancer Immunotherapy - ScienceDirect
Current issues and perspectives in PD-1 blockade cancer immunotherapy | SpringerLink
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy - Journal of Materials Chemistry B (RSC Publishing)
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? | Journal for ImmunoTherapy of Cancer | Full Text
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors | Biomarker Research | Full Text
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Early Screening of Pancreatic Cancer Immunotherapy Target Candidates | Technology Networks
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Nature Reviews Cancer
Epitope spreading is spreading success in immunotherapy
Working towards a safer and more effective oral immunotherapy – a treatment for food allergy – EAACI Patients
CXCL10: a promising marker for immunotherapy response in metastatic melanoma - UChicago Medicine
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients - Clinical Lung Cancer
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy: Trends in Immunology
The future of cancer immunotherapy: microenvironment-targeting combinations | Cell Research
Combining microenvironment normalization strategies to improve cancer immunotherapy | PNAS
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
